Simone Schierle, Moritz Helmstädter, Jurema Schmidt, Markus Hartmann, Maximiliane Horz, Astrid Kaiser, Lilia Weizel, Pascal Heitel, Anna Proschak, Victor Hernandez‐Olmos, Ewgenij Proschak, Daniel Merk
- The nuclear farnesoid X receptor (FXR) and the enzyme soluble epoxide hydrolase (sEH) are validated molecular targets to treat metabolic disorders such as non‐alcoholic steatohepatitis (NASH). Their simultaneous modulation in vivo has demonstrated a triad of anti‐NASH effects and thus may generate synergistic efficacy. Here we report dual FXR activators/sEH inhibitors derived from the anti‐asthma drug Zafirlukast. Systematic structural optimization of the scaffold has produced favorable dual potency on FXR and sEH while depleting the original cysteinyl leukotriene receptor antagonism of the lead drug. The resulting polypharmacological activity profile holds promise in the treatment of liver‐related metabolic diseases.
